By Sabela OjeaBecton Dickinson said revenue rose in the latest quarter amid commercial launches, sales and 510k Food and Drug Administration clearances. Stripping out one-time items, the company's earnings per share came in at $2.96. Analysts surveyed by FactSet had forecast lower adjusted earnings per share of $2.90. Revenue rose 5.1% to $4.9 billion, beating analysts expectations of $4.84 billion, according to FactSet. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix(END) Dow Jones NewswiresAugust 03, 2023 07:05 ET (11:05 GMT)Copyright (c) 2023 Dow Jones & Company, Inc.

Source: Wall Street Journal August 03, 2023 17:11 UTC